FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to efferent therapy, and can be used in treating autoimmune, metabolic and other diseases. That is ensured by cascade plasma filtration with using a device comprising a fractionator having one input and two outputs, supplied by a membrane filter dividing an internal volume of the fractionator on an internal and external space for a concentrate and a filtrate. The input and one of the outputs are designed to be coupled with the internal space of the fractionator, and the second output - with its external space. Before the input of the fractionator, there are mounted air trap and pressure sensor. Also, the device comprises a plasma container, a washing isotonic solution container T-jointed with a plasma or washing isotonic solution branch to the input of the fractionator, a washing liquid and/or concentrated plasma macromolecules tank connected via the branch with the output from the internal space of the fractionator. A pump segment mounted in the plasma or washing isotonic solution branch to the input of the fractionator, clamps fixed on the branches connected to the outputs of the fractionator, and also to the outputs of the plasma tank and washing isotonic solution tank. Plasma is supplied to the fractionator where it is divided on filtrate and concentrate. While dividing plasma, input pressure in the fractionator is measured, and if reaching the pressure value 100-150 mm hg, the division process is continued with taking the concentrate periodically or simultaneously to be removed from the internal space of the fractionator. The concentrate is taken at rate 5-20% of plasma perfusion rate until reaching the input pressure in the fractionator 150-250 mm hg. When reaching the maximum rate, the plasma division process is stopped that is followed with washing of the fractionator through the internal or external space, including in a continuous flow mode, then plasma division on the filtrate and concentrate is started again.
EFFECT: inventions allow providing high selectivity of target component removal, reducing loss of useful components of blood plasma.
9 cl, 3 tbl, 1 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF OPHTHALMOLOGICAL DISEASES TREATMENT | 2022 |
|
RU2798002C1 |
METHOD OF TREATING CHRONIC HEPATITIS IN CHILDREN | 2014 |
|
RU2553179C1 |
DEVICE FOR CARRYING OUT SINGLE NEEDLE MEMBRANE PLASMAPHERESIS | 2001 |
|
RU2203099C2 |
METHOD OF PROLONGING PREGNANCY IN EARLY PRE-ECLAMPSIA | 2023 |
|
RU2803574C1 |
METHOD OF TREATING JAUNDICE IN PATIENTS WITH ACUTE HEPATIC FAILURE | 2015 |
|
RU2607193C1 |
METHOD FOR EXTRACORPORAL REGENERATION OF PLASMA AFTER PLASMAPHERESIS | 1993 |
|
RU2033190C1 |
PLASMA FILTER | 2012 |
|
RU2514545C2 |
MEMBRANE FILTER AND PLASMOPHERESIS SYSTEM (VERSIONS) | 1999 |
|
RU2153389C1 |
"AUXILIARY LIVER" APPARATUS | 0 |
|
SU1424851A1 |
METHOD OF PLASMAPHERESIS IN A SINGLE-NEEDLE EXTRACORPOREAL CIRCUIT FOR ANIMALS, INCLUDING WITH LOW BODY WEIGHT, AND THE DEVICE FOR ITS IMPLEMENTATION | 2016 |
|
RU2651073C2 |
Authors
Dates
2011-06-20—Published
2010-01-12—Filed